Background: The laryngeal mask airway ProSeal™ (PLMA™), a new laryngeal mask device, was compared with the laryngeal mask airway Classic™ (LMA™) with respect to: (1) insertion success rates and times; (2) efficacy of seal; (3) fiberoptically determined anatomic position; (4) orogastric tube insertion success rates and times; (5) total intraoperative complications; and (6) postoperative sore throat in nonparalyzed adult patients undergoing general anesthesia, hypothesizing that these would be different.
A NEW laryngeal mask device, the laryngeal mask airway ProSeal™ (PLMA™), has been developed by Brain 1 with a modified cuff to improve the seal and a drainage tube to provide access to the gastrointestinal tract. Preliminary studies in anesthetized, paralyzed patients have shown that the PLMA™ is capable of achieving a more effective seal than the laryngeal mask airway Classic™ (LMA™), facilitates orogastric tube placement, isolates the glottis from the esophagus when correctly positioned, and exerts mucosal pressures similar to the LMA™. [1] [2] [3] However, there are no published data about its use in nonparalyzed patients, and the frequency of clinical problems is unknown. In the current multicenter study, we compared the LMA™ and PLMA™ with respect to: (1) insertion success rates and times; (2) efficacy of seal; (3) fiberoptically determined anatomic position; (4) orogastric tube insertion success rates and times; (5) total intraoperative complications; and (6) postoperative sore throat in nonparalyzed adult patients undergoing general anesthesia. We hypothesized that the devices were different in these areas.
Methods
Three hundred eighty-four adult patients (American Society of Anesthesiologists physical status I-II) undergoing general anesthesia for routine minor procedures were randomly assigned to have either the PLMA™ or LMA™ used for airway management. In addition, 50% of patients in each group were randomly assigned to have a gastric tube inserted orally. Eight study sites from seven countries (one each in Australia, Austria, France, Germany, Italy, and Spain, and two in the United States) participated in the study. Each study site conducted 48 cases with even randomization for the type of airway device and use of the orogastric tube. Randomization was performed by opening a sealed envelope immedi-ately before induction. Ethics committee approval was obtained from each individual study site, and written consent was obtained from all patients. All participating anesthesiologists were experienced LMA™ users (Ͼ 200 uses) and had some experience with the PLMA™ (Ͼ 20 uses). Exclusion criteria were body mass index greater than 35 kg/m 2 , cervical spine disease, a known difficult airway, mouth opening less than 2.5 cm, upper respiratory tract symptoms in the previous 10 days, surgery to be performed to the head-neck or thoracoabdominal cavities or in the lateral-prone positions, or if the patient was considered at risk of aspiration (nonfasted, gastrosophageal reflux disease). The conduct of anesthesia was divided into four phases: (1) placement phase (commencement of propofol induction to establishment of an effective airway); (2) positive pressure ventilation phase (effective airway to commencement of spontaneous breathing); (3) spontaneous breathing phase (commencement of spontaneous breathing to discontinuation of anesthesia); and (4) emergence phase (discontinuation of anesthesia until removal of the device). Unblinded trained observers collected data during the four phases of anesthesia, and blinded trained observers collected the data in the postanesthesia care unit and the following day.
Premedication with 5-15 mg oral midazolam 1 h preoperatively was permitted, if required. Anesthetic management was standardized according to the following protocol: Monitoring was applied before anesthetic induction and included an electrocardiograph, pulse oximeter, gas analyzer, noninvasive blood pressure monitor, tidal volume monitor, and airway pressure monitor. Anesthesia was administered with the patient in the supine position, with the patient's head on a standard pillow 8 cm in height. Intravenous sedation (0.02-0.03 mg/kg midazolam and 5-10 g/kg alfentanil) and oxygen via a face mask were administered. Two minutes later, anesthesia was induced using 2-3 mg/kg intravenous propofol mixed with 25 mg lidocaine given over 30 s. The patient remained anesthetized with 1-3% endtidal sevoflurane in 33% oxygen and nitrous oxide. Face mask ventilation was commenced and continued for at least 30 s until conditions were suitable for PLMA™-LMA™ insertion (loss of eyelash reflex, jaw relaxation, absence of movement, and apnea). Additional boluses of 0.5 mg/kg intravenous propofol were given as required until an adequate level of anesthesia was achieved for placement. The following cardiorespiratory and anesthesia depth data were recorded every 5 min, commencing at the start of each new phase until the device was removed: heart rate, mean blood pressure, minimal oxygen saturation (SpO 2 ), expired tidal volume, respiratory rate, peak airway pressure (positive pressure ventilation phase only), fraction of inspired oxygen, end-tidal carbon dioxide concentration, and end-tidal sevoflurane concentration.
A size 4 was used for women and a size 5 for men. A clear, water-based gel without local anesthesia was used for lubrication. Both devices were inserted and fixed according to the manufacturer's instructions. 4, 5 The PLMA™-LMA™ was connected to a circle breathing system, and the cuff was inflated with air until an effective airway was established or the maximum recommended inflation volume reached (size 4, 30 ml; size 5, 40 ml). The number of insertion attempts was recorded. A failed attempt was defined as removal of the device from the mouth. Three attempts were allowed before device use was considered a failure. If the randomized device failed, three attempts were permitted with the alternative device. The time between picking up the PLMA™-LMA™ and obtaining an effective airway was recorded. An effective airway was judged by a square wave capnograph trace and no audible leak with peak airway pressures 12 cm H 2 O or greater during gentle manual ventilation. The introducer tool was not used for the first insertion attempt with the PLMA™ but could be used for the second and third attempt. If both randomized airway devices failed during the placement phase, or if the airway device failed after the placement phase, the anesthesiologist was free to manage the airway as clinically indicated.
Once an effective airway was obtained, intracuff pressure was set at 60 cm H 2 O, and the oropharyngeal leak pressure was determined by closing the expiratory valve of the circle system at a fixed gas flow of 3 l/min, noting the airway pressure (maximum allowed ϭ 40 cm H 2 O) at which equilibrium was reached. 6 Any air entering the stomach was noted when measuring oropharyngeal leak pressure by listening over the epigastrium with a stethoscope. Orogastric tube insertion was performed manually through the drainage tube for the PLMA™ and behind the cuff for the LMA™. A 14-and 16-French size lubricated orogastric tube was used for the size 4 and 5 PLMA™-LMA™, respectively, as recommended by the manufacturer. Orogastric tube placement was not attempted with the PLMA™ if there was an air leak up the drainage tube. Correct orogastric tube placement was assessed by suction of fluid or detection of injected air by epigastric auscultation. The time taken for correct placement was recorded (picking up the orogastric tube until confirmation of placement). The number of insertion attempts was recorded. A failed attempt was defined as failure to advance the orogastric tube. Two attempts were allowed before orogastric tube insertion was considered a failure. The orogastric tube was removed immediately after insertion. Anatomic position was determined by passing a fiberoptic scope to a position just proximal to the end of the airway tube and scoring the view. 7 Anatomic position of the drainage tube (PLMA™ only) was determined by passing a fiberoptic scope to the end of the drainage tube and scoring the position, as previously described 2 Adjustments to the position of the PLMA™-LMA™ were not based on the fiberoptic view.
Patients underwent positive pressure ventilation until spontaneous breathing resumed. Intraoperative analgesia was with intravenous alfentanil, intravenous morphine, ketoralac, or infiltration of local anesthesia. Anesthesia was not discontinued until the surgery was complete to standardize conditions for the emergence phase. Patients were given 100% O 2 during emergence, and the airway device was removed when the patient was awake. The following intraoperative complications were documented: failed use, aspiration-regurgitation, hypoxia (SpO 2 Ͻ 90%), bronchospasm, airway obstruction, gastric insufflation, coughing-gagging-retching, hiccup, cough during removal, blood staining of the airway device, and tongue-lip-dental trauma. If a complication occurred, an explanation was given and the minimal SpO 2 documented. Heart rate, mean blood pressure, SpO 2 , and respiratory rate were recorded 5 min after PLMA™-LMA™ removal with the patients breathing oxygen at 4 l/min via a Hudson mask. Analgesia in the postanesthesia care unit was with morphine or ketoralac.
Patients underwent two structured interviews: (1) before leaving the postanesthesia care unit; and (2) 18 -24 h after surgery (by phone or ward interview). Patients were asked about sore throat (constant pain, independent of swallowing), sore neck, sore jaw, dysphonia (difficulty-pain on speaking), and dysphagia (difficultypain on swallowing). Symptoms were graded by the patient as mild, moderate, or severe. Patients were also asked if they were satisfied with the anesthetic (yes-no). Patients were unaware of the airway device used.
Statistics
The primary variables tested were LMA™ device insertion success rates and times, efficacy of seal, fiberoptically determined anatomic position, orogastric tube insertion success rates and times, total intraoperative respiratory complications, and postoperative sore throat. Secondary variables tested were the individual intraoperative complications (other than insertion failure) and individual postoperative complications (other than sore throat). Sample size was based on data from previous studies on the LMA™-PLMA™, 2,3,8,9 a pilot study of sore throat with the PLMA™ (found to be 14%), and the need to allow even distribution of the four randomized groups between eight study sites. The sample size allowed a projected difference of 10% or less to be detected between the groups for all of the primary variables for a type I error of 0.05 and a power of 0.95. The variable requiring the largest sample size was sore throat. If the randomized device failed and the alternative device succeeded, all variables were assigned to the initial randomized device (intention to treat). The distribution of data was determined using Kolmogorov-Smirnov analysis. Sta-tistical analysis was with paired t test (parametric data), and Kruskal-Wallis test, Mann-Whitney rank sum test, and chi-square test (nonparametric data). P Ͻ 0.05 was considered significant.
Results
Intraoperative data were 99% and postoperative data were 97% complete. Incomplete intraoperative data were a result of failure to attempt gastric tube placement (LMA™, n ϭ 23), failure to document the anatomic position of airway tube (LMA™, n ϭ 2), and failure to document the anatomic position of the drainage tube (PLMA™, n ϭ 78). Incomplete postoperative data were a result of failure to interview the patient postoperatively. There were 53 protocol deviations: desflurane was used instead of sevoflurane in six patients (PLMA™, n ϭ 3; LMA™, n ϭ 3), minor intraabdominal laparoscopic surgery was performed in six patients (PLMA™, n ϭ 3; LMA™, n ϭ 3), a nondepolarizing muscle relaxant was given to one patient (LMA™, n ϭ 1), and adjustments in intracuff pressure were made in 40 patients (PLMA™, n ϭ 19; LMA™, n ϭ 21). These patients were included in the analysis because the protocol deviations were minor and evenly distributed between groups. The French study site only completed 16 cases, and the shortfall of 32 cases was completed by the Australian site. All other sites completed their quota of 48 cases.
There were no differences between devices with respect to demographic and surgical details (table 1). There were no differences between devices with respect to doses of coinduction-induction agents and intraoperative-postoperative analgesics. First-attempt insertion success rates (LMA™, 91%; PLMA™, 82%, P ϭ 0.015) were higher for the LMA, but after three attempts success rates were similar (LMA™, 100%; PLMA™, 98%; table 2). Less time was required to achieve an effective airway with the LMA™ (LMA™, 31 Ϯ 30 s; PLMA™, 41 Ϯ 49 s; P ϭ 0.02). In all patients in whom the PLMA™ failed, the LMA™ was successfully inserted at the first attempt. There were three device failures after the placement phase. The PLMA™ failed in one patient 15 min into the positive pressure ventilation phase because of excessive oropharyngeal leak, and in one patient 30 min into the spontaneous breathing phase because of persistent stridor. The LMA™ failed in one patient 20 min into the spontaneous breathing phase because of severe laryngospasm. These patients were successfully managed by laryngoscope-guided tracheal intubation (n ϭ 2) or a cuffed oropharyngeal airway (n ϭ 1). The PLMA™ formed a more effective seal (PLMA™, 27 Ϯ 7 cm H 2 O; LMA™, 22 Ϯ 6 cm H 2 O; P Ͻ 0.0001). Fiberoptically determined anatomic position was better with the LMA™ (P Ͻ 0.0001; table 2). The fiberoptic view from the drainage tube revealed an open upper esophageal sphincter in 9% of patients (table 2) . Orogastric tube insertion was more successful (PLMA™, 88%; LMA™, 55%; P Ͻ 0.0001) and quicker (PLMA™, 22 Ϯ 18 s; LMA™, 38 Ϯ 56 s) with the PLMA (table 2) . Cardiorespiratory tolerance and anesthesia depth data were sim-ilar for both groups during all phases of anesthesia and in the postanesthesia care unit. Total intraoperative complications were similar for both groups, but the incidence of minor tongue-lip-dental trauma (P ϭ 0.02) was higher for the PLMA™, and the incidence of hiccup (P ϭ 0.03) was higher for the LMA™ (table 3) . Minor dental trauma (a chipped tooth) occurred in one patient during LMA™ insertion. Postoperative sore throat and other postoperative secondary variables were similar (table 4). Five patients said that they were not satisfied with their anesthesia management (PLMA™, n ϭ 4; LMA™, n ϭ 1). Oropharyngeal leak pressure was higher in women for both the PLMA™ (29 Ϯ 7 vs. 26 Ϯ 7 cm H 2 O; P ϭ 0.02) and LMA™ (23 Ϯ 5 vs. 21 Ϯ 6 cm H 2 O; P ϭ 0.03), but otherwise there were no differences in performance between men and women. Postoperative morbidity was unaffected by use of an orogastric tube. There were no statistical differences in the results among the study sites that completed their quota and no differences with the French site. 
Discussion
The LMA™ was easier and quicker to insert at the first attempt than the PLMA™. This confirms data from a crossover study of 60 anesthetized, paralyzed patients. 2 The increased difficulty with PLMA™ insertion probably reflects the larger cuff (impeding digital intraoral positioning and propulsion into the pharynx), the lack of a backplate (making the cuff more likely to fold over at the back of the mouth), and the need for precise tip positioning (to prevent air leaks up the drainage tube). It is possible that increased experience or initial use of the introducer tool may have improved first-time success rates. 2 Despite the increased difficulty with insertion, success rates after three attempts for the PLMA™ were high (98%) and similar to the LMA™ (100%), suggesting that both are clinically effective airway devices.
The efficacy of seal was 5 cm H 2 O higher for the PLMA™, confirming the findings of two preliminary crossover studies. 1, 2 The improved seal is probably a result of: (1) the broader proximal cuff plugging the oropharynx more effectively; (2) the second ventral cuff pressing the dorsal cuff more firmly into the periglottic tissues; and (3) the parallel, narrower tubing allowing the base of the tongue to cover the proximal cuff more effectively. The improvement in seal may be an advantage in situations in which higher airway pressures are required for positive pressure ventilation, such as in obese patients, the lithotomy-head down position, or in patients with restrictive pulmonary pathology. The better seal probably offers no advantage in the spontaneously breathing patient.
Fiberoptically determined anatomic position was better with the LMA™, confirming the findings of two preliminary crossover studies. 1, 2 This was primarily related to increased epiglottic downfolding and is probably caused by the broader proximal cuff catching the epiglottis during insertion. It has been shown in adults and children that work of breathing with the LMA™ is increased by epiglottic downfolding. 10 Because we found that respiratory variables were similar to the LMA™ during spontaneous and positive pressure ventilation, we speculate that a downfolded epiglottis does not significantly impede airflow with PLMA™, perhaps because of the accessory vent. The incidence of an open upper esophageal sphincter being visible from the drainage tube of the PLMA™ was 9% and similar to a preliminary study. 2 The clinical importance of this finding is unknown.
Orogastric tube placement was easier and quicker with the PLMA™. This is not surprising because the drainage tube aligns the orogastric tube with the upper esophageal sphincter. However, the success rate for orogastric tube placement via the PLMA™ was lower than in the preliminary crossover studies. 1, 2 This may reflect a lack of appropriate lubrication, selection of too large an orogastric tube, or folding over of the drainage tube. 11 The latter phenomenon was identified in three patients and may have occurred in a number of others since passage of the fiberoptic scope also failed. The danger of a folded drainage tube is that the standard test for malpositon-air leaking up the drainage tube during positive pressure ventilation-will not detect it. This may indirectly put the patient at increased risk of gastric insufflation and aspiration by giving the anesthesiologist a false sense of security. A simple, noninvasive method to exclude this malposition would be to pass an orogastric tube down to the end of the PLMA™ tip to verify that the drainage tube is patent. We recommend that this drainage tube test be performed if there is any tactile resistance to PLMA™ placement. It is possible that use of a larger, stiffer orogastric tube would increase success rates for the LMA™. Residual gastric fluid is commonly found in patients undergoing elective surgery. 12 Routine gastric tube placement through the PLMA™ may have a role in gastric volume reduction, but further work is required before this can be recommended. Gastric tube placement through the PLMA™ may be indicated if gastric insufflation has occurred after face mask ventilation.
We found no differences in total intraoperative complications, but there was a higher incidence of minor tongue-lip-teeth trauma for the PLMA™ and a higher incidence of hiccup for the LMA™. The increased incidence of minor tongue-lip-teeth trauma may be related to the increased difficulty with insertion. A possible explanation for the increased incidence of hiccup is that the LMA™ may stretch the hypopharynx more vigorously than the PLMA™ since the tube is more rigid, allowing more force to be transmitted. Hiccup is known to be associated with lower esophageal reflux with the LMA™ 13 and endotracheal tube. 14 There were no episodes of clinically detected regurgitation or aspiration. In principle, if the drainage tube of the PLMA™ is correctly positioned, it should provide protection from fluid regurgitation, and this is supported by a recent cadaver study. 15 However, the PLMA™ is contraindicated in nonfasted patients, in whom the endotracheal tube remains the airway device of choice.
The safety and efficacy of the PLMA™ in patients with gastroesophageal reflux, obesity, and those undergoing intraabdominal surgery is unknown. However, the classic LMA™ has been widely used in these situations, 16 -18 and the PLMA™ should be a safer alternative.
The incidence of postoperative sore throat was similar. Postoperative sore throat is probably caused by a combination of trauma on insertion and pressure exerted by the cuff against the pharyngeal mucosa. Although the number of insertion attempts was higher with the PLMA™, the incidence of blood detected on removal was similar to the LMA™, suggesting that the incidence of mucosal trauma may have been similar. It is also likely that mucosal pressures were similar because it has been shown that the PLMA™ and LMA™ exert similarly low pressures against the pharyngeal mucosa for a given cuff volume. 3 Interestingly, it has been suggested that the incidence of sore throat with the PLMA™ might be less than the LMA™ if cuff volume is reduced to the minimal required to form an effective seal since the PLMA™ exerts lower mucosal pressures for a given oropharyngeal leak pressure. 3 The incidence of intraoperative complications and postoperative sore throat was similar to previous studies in anesthetized, nonparalyzed patients for the LMA™. 9, 19 A limitation of our study is that it was conducted by experienced LMA™ users who had some experience with the PLMA™. The relative lack of experience suggests that performance might improve with the PLMA™. It has been shown that performance with the LMA™ improves over the first 75 20 and 1,500 uses. 21 The implications of our findings for the novice PLMA™ user are unknown.
We conclude that, in anesthetized, nonparalyzed patients, the LMA™ is easier and quicker to insert, but the PLMA™ forms a better seal and facilitates easier and quicker orogastric tube placement. The incidence of total intraoperative complications and postoperative sore throat is similar.
